Genomic Profiles and Clinical Outcomes of De Novo Blastoid/Pleomorphic MCL Are Distinct From Those of Transformed MCL

Blood advances - United States
doi 10.1182/bloodadvances.2019001396
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

American Society of Hematology

Related search

Outcomes Following ACL and Grade III MCL Injuries

Orthopaedic Journal of Sports Medicine
OrthopedicsSports Medicine
2017English

MCL 2006 Committees

2006English

McL-1 Ubiquitination and Destruction

Oncotarget
Oncology
2011English

In Vivo Characterization of (−)(−)mcl-144 and (+)(−)mcl-193: Isomeric, Bivalent Ligands With Mu/Kappa Agonist Properties

Neurochemical Research
MedicineBiochemistryCellularMolecular Neuroscience
2008English

Histologically Transformed Follicular Lymphoma Exhibits Protein Profiles Different From Both Non-Transformed Follicular and De Novo Diffuse Large B-Cell Lymphoma

Blood Cancer Journal
OncologyHematology
2015English

Regulation of Neutrophil Apoptosis by McL-1

Biochemical Society Transactions
Biochemistry
2004English

De Novo Acquisition of Resistance to SCY-078 in Candida Glabrata Involves FKS Mutations That Both Overlap and Are Distinct From Those Conferring Echinocandin Resistance

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2017English

McL-1 Degradation During Hepatocyte Lipoapoptosis

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2009English

Targeting McL-1 for the Therapy of Cancer

Expert Opinion on Investigational Drugs
MedicinePharmacology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy